MedPath

Effect of Prebiotics on Intestinal Gas Production, Microbiota and Digestive Symptoms

Not Applicable
Completed
Conditions
Healthy
Interventions
Dietary Supplement: Bimuno Galacto-oligo-saccharide
Registration Number
NCT02618239
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Brief Summary

Non-absorbable, fermentable residues in the diet increase intestinal gas production and induce gas-related symptoms, such as flatulence, abdominal bloating and distention; however, prebiotics, which are also fermented by colonic bacteria have been shown to improve this type of symptoms. The aim is to demonstrate changes in metabolic activity of gut microbiota and colonic biomass induced by prebiotics.

Healthy subjects (n=20) will be administered a prebiotic (Galacto-oligo-saccharide; 2.8 g/d) for 3 weeks; they will also receive a standard diet during three days. The following outcomes will be measured immediately before, at the beginning and at the end of the treatment: a) number of gas evacuations during daytime for 2 days on the standard diet, by means of an event marker; b) volume of gas evacuated via a rectal tube during 4 hours after a test meal, by means of a barostat; c) microbiota composition by fecal analysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
Exclusion Criteria
  • gastrointestinal symptoms
  • recent (3 months) antibiotic intake
  • recent (3 months) change of diet
  • recent (3 months) gastroenteritis

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Healthy subjectsBimuno Galacto-oligo-saccharideBimuno Galacto-oligo-saccharide administration 2.7 g/d x 3 weeks
Primary Outcome Measures
NameTimeMethod
Number of daily anal gas evacuationsChange from beginning of treatment (mean of days 2 and 3) to end of treatment (mean of days 20 and 21)
Secondary Outcome Measures
NameTimeMethod
Volume of anal gas evacuationChange from beginning of treatment (day 3) to end of treatment (day 21)
© Copyright 2025. All Rights Reserved by MedPath